Guggenheim lowered the firm’s price target on Nanobiotix (NBTX) to $8 from $12 and keeps a Buy rating on the shares. After the company reported FY24 earnings consistent with prior disclosures, the firm is updating its model to reflect second half results and remove assumptions for recurrent/metastatic head and neck squamous cell carcinoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix’s Promising Future: Buy Rating Backed by Data-Rich 2025 and Strategic Advancements
- Nanobiotix SA ADR Reports 2024 Financial Results
- Nanobiotix: Strategic Partnerships and Clinical Advancements Drive Buy Rating
- Nanobiotix Reports 2024 Progress and Financial Results
- Nanobiotix to Announce 2024 Financial Results and Host Conference Call